Questions raised about pivotal rivaroxaban trial

Doctors are calling for further investigation into a key trial supporting the safety of rivaroxaban, following reports its results may have been skewed by a faulty measurement device.

The ROCKET-AF trial, which involved more than 14,000 patients with non-valvular atrial fibrillation, found that rivaroxaban (Xarelto) was as effective as warfarin at preventing stroke and had a similar risk of major bleeds.